相似文献
1
Ovarian cancer immunotherapy: opportunities, progresses and challenges.
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.
2
Immunotherapy in ovarian cancer.
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
3
Ovarian cancer: designing effective vaccines and specific diagnostic tools.
Immunotherapy. 2014;6(1):35-41. doi: 10.2217/imt.13.144.
4
Immunity and immune suppression in human ovarian cancer.
Immunotherapy. 2011 Apr;3(4):539-56. doi: 10.2217/imt.11.20.
5
Emerging immunotherapies in ovarian cancer.
Discov Med. 2015 Sep;20(109):97-109.
6
Opportunities in immunotherapy of ovarian cancer.
Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. doi: 10.1093/annonc/mdw084.
7
Targeted immune therapy of ovarian cancer.
Cancer Metastasis Rev. 2015 Mar;34(1):53-74. doi: 10.1007/s10555-014-9540-2.
8
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9. doi: 10.1093/jnci/87.19.1463.
9
Immunologic approaches to ovarian cancer treatment.
J Clin Oncol. 2007 Jul 10;25(20):2884-93. doi: 10.1200/JCO.2007.11.0775.
10
Immunotherapy in Ovarian Cancer.
Surg Oncol Clin N Am. 2019 Jul;28(3):447-464. doi: 10.1016/j.soc.2019.02.002. Epub 2019 Apr 5.
引用本文的文献
1
The Role of the Plasminogen Activator Inhibitor 1 ( ) in Ovarian Cancer: Mechanisms and Therapeutic Implications.
Glob Med Genet. 2024 Oct 29;11(4):358-365. doi: 10.1055/s-0044-1791734. eCollection 2024 Dec.
2
CD4CCR8 Tregs in ovarian cancer: a potential effector Tregs for immune regulation.
J Transl Med. 2023 Nov 10;21(1):803. doi: 10.1186/s12967-023-04686-3.
3
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.
Exp Suppl. 2022;113:1-57. doi: 10.1007/978-3-030-91311-3_1.
4
Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.
Adv Ther (Weinh). 2020 Nov;3(11). doi: 10.1002/adtp.202000144. Epub 2020 Aug 16.
5
microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.
J Ovarian Res. 2020 Sep 18;13(1):110. doi: 10.1186/s13048-020-00720-w.
6
MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.
Inflammation. 2019 Oct;42(5):1517-1529. doi: 10.1007/s10753-019-01004-2.
7
Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues.
Oncotarget. 2018 Nov 30;9(94):36666-36683. doi: 10.18632/oncotarget.26378.
8
Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.
J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
9
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.
Cancer Manag Res. 2017 Oct 31;9:553-563. doi: 10.2147/CMAR.S116683. eCollection 2017.
10
The immunopeptidomic landscape of ovarian carcinomas.
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951. doi: 10.1073/pnas.1707658114. Epub 2017 Nov 1.
本文引用的文献
1
Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma.
J Hematol Oncol. 2009 Aug 27;2:37. doi: 10.1186/1756-8722-2-37.
2
A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.
Gynecol Oncol. 2009 May;113(2):210-5. doi: 10.1016/j.ygyno.2009.02.007. Epub 2009 Mar 4.
3
Heat-shock proteins in infection-mediated inflammation-induced tumorigenesis.
J Hematol Oncol. 2009 Jan 30;2:5. doi: 10.1186/1756-8722-2-5.
4
Activation of NK cells by extracellular heat shock protein 70 through induction of NKG2D ligands on dendritic cells.
Cancer Immun. 2008 Jul 10;8:12.
5
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
Lancet. 2008 Jul 12;372(9633):145-154. doi: 10.1016/S0140-6736(08)60697-2. Epub 2008 Jul 3.
6
CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer.
J Immunother. 2008 Feb-Mar;31(2):207-14. doi: 10.1097/CJI.0b013e31816060ce.
7
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Clin Cancer Res. 2008 May 1;14(9):2740-8. doi: 10.1158/1078-0432.CCR-07-4619.
8
Tumor escape mechanism governed by myeloid-derived suppressor cells.
Cancer Res. 2008 Apr 15;68(8):2561-3. doi: 10.1158/0008-5472.CAN-07-6229.
9
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings.
Br J Cancer. 2008 Apr 22;98(8):1336-41. doi: 10.1038/sj.bjc.6604266. Epub 2008 Mar 25.
10
Immunotherapy opportunities in ovarian cancer.
Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57. doi: 10.1586/14737140.8.2.243.
Zotero 插件